Our data demonstrated that stereotactic midbrain delivered rAAV2‐SLC6A3 gene therapy provides correction of DAT function with clear safety in the mouse model of DTDS, thereby accelerating the route to clinic. This evidence concerns the gene SLC6A3 and SLC6A3-related dopamine transporter deficiency syndrome.